Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 nov. 2022 07h30 HE | Source: Adaptive Biotechnologies

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

>95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey85% of surveyed patients have heard of MRD testing, yet...
03 nov. 2022 16h05 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
11 oct. 2022 08h05 HE | Source: Adaptive Biotechnologies

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers

SEATTLE, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
05 oct. 2022 16h05 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system...
12 sept. 2022 08h30 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system...
02 sept. 2022 08h00 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
03 août 2022 16h05 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
28 juil. 2022 07h30 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
08 juil. 2022 16h05 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune...
15 juin 2022 07h30 HE | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

SEATTLE, June 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...

Page précédente

Page suivante